A healthcare startup can survive a pitch meeting and still die in a clinic. The investor admires the market size. The founder demonstrates the software. Then a nurse notices that the extra screen adds four minutes to an already impossible shift, or a physician asks who will pay for the test, or a hospital buyer points to the integration queue. The idea was clever. The workflow was not.
Global Health Impact Network & Funds, usually shortened to GHIN&F, was built around that awkward handoff between invention and use. Based in San Ramon, on the eastern edge of the San Francisco Bay Area, the organization pairs a professional network of clinicians with venture funds that invest in early-stage healthcare companies. The premise is almost plain enough to miss: medical technology should face medical judgment before large amounts of money and time harden it into a product.
Gary Goldman, a physician, dentist, anesthesiologist and healthcare informatics veteran, founded the organization in 2019. His professional biography describes years spent at the junction of clinical practice and technology, including work on electronic health records. That history matters. A digital-health product is rarely just a piece of software. It arrives in a place governed by regulation, reimbursement, habits, scarce minutes and human risk.
A network that does actual work
GHIN&F says its network includes more than 2,000 clinicians across 40 medical fields, with more than 20 years of clinical experience on average. A May 2026 partnership announcement uses a broader count of 3,000-plus clinicians and subject-matter experts. The figures are company-reported, but the operating idea is visible: members are not assembled merely to fill an advisory page.
Clinicians can join communities, continue their education, attend events and learn about finance and startup methods. They can also consult, mentor, participate in due diligence and, if eligible, become investors in the funds. Founders receive product feedback, introductions to hospital systems and corporations, help with commercialization and access to specialists who understand the problem without a forty-slide anatomy lesson.
That makes GHIN&F part venture firm, part expert network and part professional community. Each element improves the others. A large specialist network sharpens diligence. Interesting investment opportunities give clinicians a reason to stay involved. Portfolio work creates fresh operating knowledge. The fund, in turn, gives the network a consequence beyond conversation.
“There was even a difference in pitching to GHIF. We didn’t have to explain the problem.”Neil Ray, founder and CEO of Raydiant Oximetry
What the fund buys - and what it brings
The fund side focuses on early-stage healthcare, with stated interests in digital health, medical technology and precision medicine in the United States and Europe. Its public portfolio is small enough to read as a map of clinical friction. Elemeno Health works on support for nurses and frontline teams. Elucid uses artificial intelligence to inform cardiovascular treatment decisions. Plethy offers musculoskeletal-care programs. Raydiant Oximetry is developing technology for maternal and fetal monitoring. Somnoware built software for sleep and respiratory-care workflows.
GHIN&F says its first fund, launched in 2019, was fully subscribed at $10 million. By June 2025, the firm reported ten investments and two exits. Somnoware was acquired by ResMed in 2023; the fund says that investment returned 3.3 times capital. UBERDOC, a service offering priority access to doctors, was acquired by ROV Investment Partners in 2025, according to GHIN&F.
Those results belong in context. They are the firm's own account, and a ten-company portfolio is not a decades-long record. Still, the exits show the network-fund model has moved beyond a community experiment. GHIF II was described in 2025 as live and actively fundraising, with a $50 million target and a planned first close at $25 million. The organization said 40 percent of the first fund’s limited partners had committed again.
A different kind of diligence
Traditional healthcare venture firms also hire physicians, maintain adviser networks and call experts. GHIN&F's difference is structural rather than magical: the clinician community is positioned as the infrastructure, not an accessory. In an interview, General Partner and CFO Sheetal Nariani said that if a neuroscience company approaches the fund, it can consult 10 to 20 relevant experts about clinical need, product-market fit and the likelihood of adoption.
Nariani's own background combines microbiology, finance and work at pharmaceutical companies including Novartis, Cipla and Wockhardt. Her description of startup assessment is notably unromantic. Young companies have little useful history, so she looks for “financial hygiene”: whether founders understand cash, build plausible forecasts, account for regulatory pathways and can explain how a product reaches the market. Clinical enthusiasm does not excuse poor finance. Neat financial models do not compensate for a product clinicians will ignore.
“The biggest factor to our success is the presence of a clinician in the boardroom.”Sheetal Nariani, General Partner and CFO
For founders, the practical benefit is compression. A credible specialist can identify a fatal assumption early, introduce a trial site, explain a hospital buying process or validate that a stubborn problem is real. For clinician members, the attraction runs in the other direction. They gain a route into innovation that is more active than attending a demo and less lonely than becoming an angel investor on their own.
Two customers, one hard problem
The organization serves two constituencies whose incentives do not naturally line up. Clinicians are paid to deliver care safely and consistently. Startup founders are rewarded for speed, experimentation and growth. The clinician sees interruptions and liability where a founder may see engagement. The founder sees a scalable platform where a hospital may see a new procurement cycle. GHIN&F tries to make those disagreements useful before they become expensive.
For a young company, the service is not simply access to famous doctors. It is access to people who can ask narrow, operational questions. Does the proposed user control the budget? Will the result arrive early enough to change treatment? Does the device create another cleaning protocol? Is the algorithm trained on patients who resemble the intended population? The answers can influence a product roadmap, a clinical study and a sales pitch at once.
For clinicians, the network offers a different form of leverage. A physician who has watched the same failure recur for years may not want to leave practice and found a company. Through GHIN, that person can advise a team, review an opportunity or help with diligence. The network also publishes interviews and newsletters, and runs events on subjects including cardiovascular AI, women’s health, longevity and dental technology. Education is the on-ramp; participation is the deeper product.
The business behind the community
The model has several economic layers. The venture funds seek conventional returns from equity ownership in portfolio companies. Limited partners supply capital and may also contribute domain expertise. Network participation feeds diligence and post-investment support. Public pages do not disclose membership prices, management fees or carried-interest terms, so the precise revenue mix remains private.
The newest layer looks more like a service business. In May 2026, GHIN formalized a European partnership with Sojo.consulting after nine months of pilots. Together they offer clinical and commercial diligence to European medtech founders, venture firms and corporate partners seeking a clearer route into the United States. Sojo manages European client relationships; GHIN supplies named clinical access and U.S. expertise. It is the network converted into a productized bridge across the Atlantic.
A separate joint venture with Revere Partners focuses on dental and oral-systemic health. The rationale is partly personal - Goldman trained as a dentist - and partly an inefficiency thesis. The partners cited data suggesting oral-health companies receive a tiny share of healthcare venture investment despite the scale of dental spending. Revere contributes category focus; GHIN&F contributes a broad physician and dentist network for diligence and go-to-market support.
Where it fits
GHIN&F sits between specialist venture capital, expert networks such as GLG and Guidepoint, healthcare accelerators and clinical consultancies. A founder could assemble those functions separately: raise from a conventional investor, pay for expert calls, recruit advisers and hire a market-access firm. GHIN&F's pitch is that the pieces work better when the same community runs through all of them.
That position also makes the company a business-to-business platform rather than a healthcare provider. Patients are the intended beneficiaries of safer maternal monitoring, better cardiovascular decisions or smoother respiratory care, but GHIN&F does not diagnose or treat them. Its direct market is the layer behind care: founders, investors, clinical experts, hospital relationships and corporate partners deciding which tools move forward.
The risk is the mirror image of the advantage. Networks need active members, not just impressive counts. Expert consensus can punish strange but valuable ideas. Clinicians understand care, but they do not automatically understand distribution, pricing or venture-scale growth. A larger second fund would also have to find more investments without diluting the specialist attention that made the first fund distinctive.
Yet healthcare has no shortage of products designed around an abstract user and delivered to an exhausted real one. GHIN&F is an attempt to close that distance. Its most useful product may not be the fund or the member platform. It may be the meeting where a clinician recognizes the problem, a founder hears the objection early, and an investment decision gets a little less theoretical.